Taken together, our results support the early formation of SARS-CoV-2-specific CD19+ and CD19− presumably long-lived plasma cells in the human BM after repeated mRNA vaccination against SARS-CoV-2, as an important prerequisite for durable serological immunity preventing severe courses of COVID-19. The gene discussed is CD19; the disease is COVID-19.